24/7 Wall Street
12 Jun 2026, 11:35 UTC · 3h ago
The Death Cross Is Lying: Why Wall Street Is Still Loading Up on Hershey and Vertex
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
24/7 Wall Street
12 Jun 2026, 11:35 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Vertex Pharmaceuticals' povetacicept BLA for IgA nephropathy is currently under a six-month FDA Priority Review. — Regulatory approvals for new drug indications are high-impact binary catalysts that typically drive significant stock price movement.
+0.60Hershey reaffirmed its FY2026 adjusted EPS guidance of $8.20 to $8.52, implying low-double-digit growth. — Reaffirmed positive guidance provides a fundamental floor for the stock and supports bullish analyst price targets.
+0.40Vertex Pharmaceuticals reported Q1 2026 non-GAAP EPS of $4.47, beating estimates and seeing operating income rise 80.62% year over year. — Strong earnings growth and operating leverage validate the company's diversification thesis and fundamental strength.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Both Hershey and Vertex Pharmaceuticals have triggered 'death cross' technical signals, though the gap between their 50-day and 200-day moving averages is minimal. — While technically bearish, the article argues the signal is 'mechanically valid but informationally weak,' limiting its downward pressure.
-0.20Which stocks this story touches
Strong earnings momentum, significant cash growth, and a pending FDA priority review for a new drug catalyst.
Despite a 'death cross' technical signal, the company had a Q1 earnings beat and reaffirmed positive full-year guidance.
Mentioned only as a historical reference for an analyst's previous success.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
2h ago
